1. Kurmasheva N, Said A, Wong B, Kress A, Liu Z, Wang C, Carter-Timofte ME, Holm E, van der Horst D, et al..., Olagnier D. 4-octyl-Itaconate enhances VSVd51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways. Nature Communications 2024. 15, 4096. https://doi.org/10.1038/s41467-024-48422-x.
2. van der Horst D, Marqvorsen M, Assil S, Kurmasheva N, Wu Q, Zhao J, Cesari E, Rahimic A, Iversen MB, et al..., Olagnier D.SAM68 directs STING signaling to apoptosis in macrophages. Communications Biology. 2024 Mar 7;7(1):283. doi: 10.1038/s42003-024-05969-1.
3. van der Horst D, Carter-Timofte ME, van Grevenynghe J, Laguette N, Dinkova-Kostova AT, Olagnier D. Regulation of innate immunity by Nrf2. Current Opinion in Immunology. 2022 Oct;78:102247. doi: 10.1016/j.coi.2022.102247. Epub 2022 Sep 26.
4. Casares L, Moreno R, Ali KX, Higgins M, Dayalan Naidu S, Neill G, Cassin L, Kiib AE, Svenningsen EB, et al..., Olagnier D*, de la Vega L*. The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity. Redox Biology. 2022 May;51:102291. doi: 10.1016/j.redox.2022.102291. Epub 2022 Mar 17.* co-senior authors.
5. Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS,Chen A, Crupi MJF, et al..., Diallo JS. Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. Molecular Therapy. 2022 May 6:S1525-0016(22)00296-9. doi: 10.1016/j.ymthe.2022.04.025.
6. Carter-Timofte ME, Arulanandam R, Kurmasheva N, Fu K, Taha Z, Cassin L, van der Horst D, van der Sluis R, JacobsD, et al..., Olagnier D. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. ACS Infect Diseases. 2021 Nov 12;7(11):3034-3051. doi: 10.1021/acsinfecdis.1c00278. Epub 2021 Oct 18.
7. Loucif H, Dagenais-Lussier X, Beji C, Cassin L, Routy JP, Olagnier D, van Grevenynghe J. Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T-cells. Autophagy. 2021 Oct 6:1-18. doi: 10.1080/15548627.2021.1972403.
8. Loucif H, Dagenais-Lussier X, Beji C, Cassin L, Jrade H, Tellitchenko R, Routy JP, Olagnier D, van Grevenynghe J. Lipophagy confers a key metabolic advantage that ensures protective CD8 T cell responses against HIV-1. Autophagy. 2021 Jan 18:1-16. doi: 10.1080/15548627.2021.1874134.
9. Schneider Hait A*, Olagnier D*, Sancho-Chimizu V, Skipper KA, Helleberg M, Larsen SM, Bodda C, Moldovan LI, Ren F, et al..., Mogensen TH. Defects in LC3B2 and ATG4A underlie HSV2 meningitis and reveal a critical role for autophagy in antiviral defences in humans. * first co-authors. Science Immunology. 2020 Dec 11;5(54):eabc2691. doi: 10.1126/sciimmunol.abc2691.
10. Olagnier D, Farahani E, Herengt A, Thyrsted J, Cadanet J, Idorn M, Hait A, Hernaez B, Knudsen A, et al..., Holm CK. SARS-CoV2-mediated suppression of NRF2 signaling reveals a potentantiviral activity of 4-octyl-itaconate and dimethyl fumarate. 2020. Nature Communications 11, 4938 (2020).
11. Zhang BC, Nandakumar R, Reinert L, Huang J, Laustsen A, Gao Z, Sun C, Jensen S, Troldborg A, et al..., Paludan SR. STEEP mediates STING ER exit and activation of signaling. Nature Immunology. 2020 Aug;21(8):868-879. doi: 10.1038/s41590-020-0730-5.
12. Gunterstofte C, Iversen MB, Peri S, Thielke A, Balachandran S, Holm CK, Olagnier D. Nrf2 negatively regulates type I IFN responses and increases susceptibility to genital herpes infection in mice. 2019. Frontiers in Immunology. doi 10.3389/fimmu.2019.02101
13. Olagnier D, Brandtoft AM, Gunderstofte C, Villadsen NJ, Krapp C, Thielke AL, Laustsen A, Peri S, HansenAL, et al..., Holm CK. Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming. Nature Communications. 2018 Aug 29;9(1):3506. doi: 10.1038/s41467-018-05861-7
14. Hansen AL, Buchan GJ, Rühl M, Mukai K, Salvatore S, Ogawa E, Andersen SD, Iversen MB, Thielke AL, et al..., Holm CK. Identification of endogenous nitro-fatty acids as inhibitors of STING signaling. PNAS. 2018 Aug 14;115(33):E7768-E7775. doi: 10.1073/pnas.1806239115.
15. Hansen AL, Brandtoft AM, Thielke A, Nyegaard M, Olagnier D*, Holm CK*. Global transcriptional changes in response to cGAMP depend on STING in human THP-1 cells. * co-senior authors. Cellular and Molecular Immunology. 2018 May. doi: 10.1038/s41423-018-0035.
16. Olagnier D, Lababidi R, Belhadj S, Sze A, Liu Y, Naidu Dayalan S, Ferrari M, Jiang Y, Chiang C, et al..., Lin R. Activation of Nrf2 signaling augments vesicular stomatitis virus-based oncolysis via autophagy driven suppression of antiviral immunity. Molecular Therapy. 2017 May 17. pii: S1525-0016(17)30206-X.
17. Olagnier D, Hiscott J. Type I and type III IFN-induced immune responses: it’s a matter of kinetics and intensity. Hepatology. 2014 Apr;59(4):1225-8. doi: 10.1002/hep.26959.
18. Sze A, Belgnaoui SM, Olagnier D, Lin R, Hiscott J, van Grevenynghe J. Host Restriction Factor SAMHD1 Limits Human T Cell Leukemia Virus Type 1 Infection of Monocytes via STING-Mediated Apoptosis. Cell Host and Microbe. 2013 Oct 16;14(4):422-34. doi: 10.1016/j.chom.2013.09.009.
19. Lefèvre L, Lugo-Villarino G, Meunier E, Valentin A, Olagnier D, Authier H, Duval C, Dardenne C, Bernad J, et al..., Coste A. The C-type Lectin Receptors Dectin-1, MR, and SIGNR3 Contribute Both Positively and Negatively to the Macrophage Response to Leishmania infantum. Immunity. 2013 May 14. doi:pii: S1074-7613(13)00195-7.
20. Olagnier D, Hiscott J. Breaking the barrier: membrane fusion triggers innate antiviral immunity. Nature Immunology. 2012 Jul 19;13(8):713-5. doi: 10.1038/ni.2373